Wednesday, April 30, 2014 10:16:53 AM
Today : Wednesday 30 April 2014
NeoStem, Inc. (Nasdaq:NBS) and its subsidiary, Progenitor Cell Therapy, LLC ("PCT"), announced the execution of a Services Agreement with IRX Therapeutics, Inc. ("IRX") under which PCT will provide services to support IRX's development of IRX-2, a primary cell-derived biologic with multiple active cytokine components. IRX-2 is a cancer therapeutic designed to activate a patient's immune system to broadly restore immunity and overcome cancer-induced immune suppression. IRX has engaged PCT for the manufacture of an intermediate component referred to as IRX-2 Drug Substance for human clinical trials.
"We are pleased to reengage with IRX, a leader in advanced therapies for treatment of cancers, continuing our multi-year relationship with this client," said Dr. Robert A. Preti, President of PCT and Chief Scientific Officer of PCT and NeoStem. "We believe that PCT offers industry-leading experience and expertise that will continue to support IRX's development of IRX-2 for human clinical trials."
"We are excited to be working with one of the premier contract manufacturers, Progenitor Cell Therapy, in their Allendale facility. The expanded facility and experienced team will both help ensure that our product is manufactured to cGMP standards in a timely and efficient manner," added Jeffrey Hwang, Chief Financial Officer and Acting Chief Operating Officer of IRX.
"This in an exciting time for PCT, with multiple new agreements with cell therapy companies, renewals of engagements, and advances in its services, including the expansion of PCT's Engineering & Innovation Center," said Dr. Robin L. Smith, Chairman and CEO of NeoStem. "We are proud of the work that PCT does to support the cell therapy industry."
About NeoStem, Inc.
NeoStem is a leader in the emerging cellular therapy industry, pursuing the preservation and enhancement of human health globally through the development of cell based therapeutics that prevent, treat or cure disease by repairing and replacing damaged or aged tissue, cells and organs and restoring their normal function. The business includes the development of novel proprietary cell therapy products as well as a revenue-generating contract development and manufacturing service business. This combination has created an organization with unique capabilities for cost effective in-house product development and immediate revenue and cash flow generation. www.neostem.com
About PCT
Progenitor Cell Therapy (PCT), a wholly owned subsidiary of NeoStem, Inc., is a leading contract development and manufacturing organization in the cellular therapy industry. For over 15 years, PCT has provided pre-clinical and clinical cGMP development and manufacturing services to more than 100 clients, advancing regenerative medicine product candidates from the development stage all the way through to human testing. PCT has two cGMP-compliant, state-of-the art facilities in New Jersey and California to serve the cell therapy industry and offers manufacturing of cell therapy-based products, engineering and innovation services, process and product development, cell and tissue processing, collection and storage, regulatory consulting, facility design, validation, and due diligence evaluations. www.pctcelltherapy.com
About IRX Therapeutics
IRX Therapeutics is a privately held company that develops immune therapies to treat cancer and related diseases. The company's therapies are designed to target and restore the immune system in order to improve a patient's response to next-generation cancer vaccines and novel targeted therapeutics. IRX Therapeutics was founded by John W. Hadden, M.D., a pioneer in the field of Immunopharmacology. The company's product platform under development, which is based on over 30 years of research by Dr. Hadden, seeks to restore the immune system of cancer patients, which is suppressed by the onset of the disease. www.irxtherapeutics.com
Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements reflect management's current expectations, as of the date of this press release, and involve certain risks and uncertainties. Forward-looking statements include statements herein with respect to the successful execution of the Company's business strategy, including with respect to the Company's ability to consummate the CSC acquisition and the Company's ability to develop and grow its business, the successful development of cellular therapies, including with respect to the Company's research and development and clinical evaluation efforts in connection with the Company's CD34 Cell Program and T Regulatory Cell Program and other cell therapies (including Melapuldencel-T if CSC is successfully acquired), the future of the regenerative medicine industry and the role of stem cells and cellular therapy in that industry and the performance and planned expansion of the Company's contract development and manufacturing business. The Company's actual results could differ materially from those anticipated in these forward-looking statements as a result of various factors. Factors that could cause future results to materially differ from the recent results or those projected in forward-looking statements include the "Risk Factors" described in the Company's Annual Report on Form 10-K filed with the Securities and Exchange Commission on March 13, 2014 and in the Company's periodic filings with the SEC. The Company's further development is highly dependent on future medical and research developments and market acceptance, which is outside its control.
CONTACT: Investor Contact:
LifeSci Advisors, LLC
Michael Rice
Founding Partner
Phone: +1-646-597-6979
Email: mrice@lifesciadvisors.com
Media Contact:
NeoStem, Inc.
Eric Powers
Manager of Communications and Marketing
Phone: +1-212-584-4173
Email: epowers@neostem.com
Recent LSTA News
- Lisata Therapeutics Announces First Patient Treated in the Second-line Cholangiocarcinoma Cohort of the BOLSTER Trial • GlobeNewswire Inc. • 09/17/2024 12:00:00 PM
- Lisata Therapeutics to Participate in Upcoming September 2024 Industry and Investor Events • GlobeNewswire Inc. • 09/09/2024 12:00:00 PM
- Lisata Therapeutics’ Certepetide Granted FDA Orphan Drug Designation for the Treatment of Cholangiocarcinoma • GlobeNewswire Inc. • 09/05/2024 12:00:00 PM
- Lisata Therapeutics Reports Second Quarter 2024 Financial Results and Provides Business Update • GlobeNewswire Inc. • 08/12/2024 08:05:00 PM
- Lisata Therapeutics to Report Second Quarter 2024 Financial Results and Provide a Business Update on Monday, August 12, 2024 • GlobeNewswire Inc. • 08/05/2024 12:00:00 PM
- Haystack Oncology and Lisata Therapeutics Initiate Research Collaboration to Use the Haystack MRD™ Technology to Evaluate Efficacy of Pancreatic Cancer Therapy • GlobeNewswire Inc. • 07/18/2024 12:00:00 PM
- Lisata Therapeutics Announces Completion of Enrollment in its Phase 2a BOLSTER Trial of Certepetide in First-Line Cholangiocarcinoma • GlobeNewswire Inc. • 07/16/2024 12:00:00 PM
- Lisata Therapeutics’ Certepetide Shows Promise in Improving Standard Treatment for Intrahepatic Cholangiocarcinoma in a Preclinical Model • GlobeNewswire Inc. • 07/10/2024 12:00:00 PM
- Lisata Therapeutics Announces Full Enrollment of Pancreatic Cancer Cohort of CENDIFOX Trial • GlobeNewswire Inc. • 06/13/2024 12:30:00 PM
- Lisata Therapeutics to Participate in Upcoming June 2024 Industry and Investor Events • GlobeNewswire Inc. • 05/28/2024 12:30:00 PM
- Lisata Therapeutics Receives Paediatric Investigation Plan Waiver from the European Medicines Agency for Certepetide in Pancreatic Cancer • GlobeNewswire Inc. • 05/20/2024 12:30:00 PM
- Form EFFECT - Notice of Effectiveness • Edgar (US Regulatory) • 05/10/2024 04:15:16 AM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 05/09/2024 08:13:47 PM
- Lisata Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Update • GlobeNewswire Inc. • 05/09/2024 08:05:00 PM
- Lisata Therapeutics to Participate in Upcoming May 2024 Industry and Investor Events • GlobeNewswire Inc. • 05/08/2024 12:00:00 PM
- Lisata Therapeutics to Report First Quarter 2024 Financial Results and Provide a Business Update on Thursday, May 9, 2024 • GlobeNewswire Inc. • 05/02/2024 12:00:00 PM
- Lisata Therapeutics and Qilu Pharmaceutical Announce First Patient Treated in Qilu’s Phase 2 Trial in China of LSTA1 in Patients with Metastatic Pancreatic Ductal Adenocarcinoma • GlobeNewswire Inc. • 04/23/2024 11:30:00 AM
- Lisata Therapeutics Announces U.S. FDA Orphan Drug Designation Granted to LSTA1 for the Treatment of Osteosarcoma • GlobeNewswire Inc. • 04/09/2024 12:30:00 PM
- Lisata Therapeutics to Participate in Upcoming April 2024 Industry and Investor Events • GlobeNewswire Inc. • 04/03/2024 12:30:00 PM
- Lisata Therapeutics Announces U.S. FDA Rare Pediatric Disease Designation Granted to LSTA1 for the Treatment of Osteosarcoma • GlobeNewswire Inc. • 03/21/2024 12:00:00 PM
- Lisata Therapeutics to Present at the Life Science Investor Forum on March 7ᵗʰ • GlobeNewswire Inc. • 03/04/2024 01:00:00 PM
- Lisata Therapeutics Reports Full Year 2023 Financial Results and Provides Business Update • GlobeNewswire Inc. • 02/29/2024 09:05:00 PM
- Lisata Therapeutics to Host Year-End 2023 Conference Call on Thursday, February 29, 2024 at 4:30 p.m. Eastern Time • GlobeNewswire Inc. • 02/22/2024 01:00:00 PM
- Lisata Therapeutics to Present at BIO CEO & Investor Conference • GlobeNewswire Inc. • 02/20/2024 01:00:00 PM
- Lisata Therapeutics to Present at the Sequire Investor Summit in Puerto Rico • GlobeNewswire Inc. • 01/18/2024 01:30:00 PM
FEATURED Cannabix Technologies and Omega Laboratories Inc. Advance Marijuana Breathalyzer Technology - Dr. Bruce Goldberger to Present at Society of Forensic Toxicologists Conference • Sep 24, 2024 8:50 AM
FEATURED Integrated Ventures, Inc Announces Strategic Partnership For GLP-1 (Semaglutide) Procurement Through MedWell USA, LLC. • Sep 24, 2024 8:45 AM
Avant Technologies Accelerates Creation of AI-Powered Platform to Revolutionize Patient Care • AVAI • Sep 24, 2024 8:00 AM
VHAI - Vocodia Partners with Leading Political Super PACs to Revolutionize Fundraising Efforts • VHAI • Sep 19, 2024 11:48 AM
Dear Cashmere Group Holding Co. AKA Swifty Global Signs Binding Letter of Intent to be Acquired by Signing Day Sports • DRCR • Sep 19, 2024 10:26 AM
HealthLynked Launches Virtual Urgent Care Through Partnership with Lyric Health. • HLYK • Sep 19, 2024 8:00 AM